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Estimation of bulky lymph nodes by power Doppler
ultrasound scanning in patients with Hodgkin’s
lymphoma: a prospective study
Size and extension of lymphadeno-pathies are important factors in defin-ing the prognosis and designing the
most appropriate treatment in Hodgkin’s
lymphoma, bulky disease and advanced
stage being recognized adverse prognostic
factors.1 In many institutions, clinical and
computed tomography (CT) examination
are considered to provide sufficient informa-
tion to map disease sites and estimate tumor
burden.1 However, non-palpable histologi-
cally significant malignant lymph nodes or
enlarged reactive or necrotic lymph nodes
may bias such a staging procedure.2 High-
resolution ultrasound (US) with power
Doppler is a recent imaging technique that
accurately defines the morphologic and vas-
cular characteristics of a lymph node. Power
Doppler US has proven useful to identify
malignant lesions, detecting more flow sig-
nals than gray-scale and color Doppler US.3,4
We tested the accuracy of power Doppler
US in detecting bulky lymph nodes in
patients with Hodgkin’s lymphoma at initial
presentation, verifying its prognostic rele-
vance.
Design and Methods
Study design
In four years, 137 consecutive newly diag-
nosed Hodgkin’s lymphoma patients were
submitted to staging procedures. The lymph
nodes most suspected of having bulky char-
acteristics were detected using clinical/CT
scan examination and power Doppler US in
all patients. The study aim was to compare
the value of power Doppler US-defined
bulky disease with that of clinical/CT-
defined bulky disease in predicting freedom
from treatment failure (FFTF). In addition,
other clinical variables routinely used as
prognostic factors were evaluated in the sta-
tistical analysis.5 Patients were informed of
the study aim, and signed a consent form
according to the Helsinki declaration.
Clinical/CT scan evaluation
Lymph node evaluation was performed by
physical examination and CT using a multi-
row helical instrument and i.v. contrast
medium (Mx 8000; Marconi Medical
Systems, Cleveland, OH, USA). For each
patient, the region containing a bulky dis-
ease, defined as any lymph node mass with
a long axis ≥5 cm, was looked for and
recorded.
Power Doppler US procedure
Patients underwent US exploration of all
superficial lymph node areas and any abnor-
mal lymph node was examined by power
Doppler, using a high-resolution US instru-
ment equipped with power Doppler (EUB
6500; Hitachi, Tokjo, Japan) and a 13-6MHz
broad-band linear probe. Lymph nodes were
assessed by gray-scale to define their
anatomic site, depth, size, shape and hilus
and by power Doppler to investigate their
intranodal vascularization.6 Size was studied
by measuring the perimeter, cross-sectional
diameter and area (defined as the maximum
measurements with nodal borders and
angles clearly defined); thereafter, the vol-
ume in mL was automatically calculated by
the US machine software. As for Doppler
spectral analysis, the resistive index (RI) of
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The accuracy of standard methods in estimating bulky lesions requires validation. We
used clinical/computed tomography (CT) evaluation and power Doppler ultrasound (US)
to detect bulky disease in 137 consecutive Hodgkin’s lymphoma patients, and ana-
lyzed the prognostic relevance of each method. Bulky disease was detected by clini-
cal/CT evaluation in 47% of the patients and by power Doppler US in 20%. After treat-
ment, at multivariate analysis power Doppler US-selected bulky disease was the param-
eter that best correlated with freedom from treatment failure (p<0.001). Power Doppler
US, a readily available imaging technique, provides a better prognostic classification by
detecting true bulky disease more accurately.
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Bulky disease estimated by power Doppler US
arterial vessels was calculated as defined by Pourcelot.7
The presence of an abnormal vascular pattern combined
with a RI value ≥0.65 fulfilled the requirement for intra-
nodal hypervascularization. The combination of vol-
ume ≥30 mL and intranodal hypervascularization was
the main criterion used to define a lymph node as bulky.
In 13 patients the bulky lymph node was studied by
repeated US volume measurements on two occasions at
1-hour intervals by the same operator (to test intraob-
server reproducibility) and by another operator
unaware of the previous result, always using the same
US machine (to test interobserver reproducibility). The
same 13 patients underwent whole-body fluorine-18-
fluoro deoxyglucose positron emission tomography
(FDG-PET)/CT scans, to examine the correlation
between bulky lymph nodes selected by power
Doppler US and those selected by PET/CT [the superfi-
cial mass with the highest standardized uptake value
(SUV) and with 3-dimensional volume ≥30 mL].8
Therapeutic plan and response evaluation 
All patients underwent ABVD-like chemotherapy
courses repeated every 4 weeks. The response to
chemotherapy was defined according to standardized
criteria.9,10 All patients considered responders received
involved field radiation with a linear accelerator
(planned dose 32Gy, without boost on initial bulky
sites).
Statistical analysis
Univariate and multivariate analyses based on the Cox
proportional hazards regression model were carried out to
assess the prognostic factors significantly contributing to
FFTF. Other statistical evaluations included χ2, unpaired
Student’s t test, and analysis of variance with Bonferroni’s
correction. SPSS for Windows (version 12.0; SPSS,
Chicago, IL, USA) was the software used.
Results
The patients’ characteristics are summarized in Table 1.
All patients received six courses of chemotherapy, in a
median time of 6 months. A total of 125 patients (91%)
achieved complete responses and underwent radiothera-
py as planned. Patients were then observed for a median
of 20 months (range, 7-43); 117 of them remained in sus-
tained complete remission. Overall, a total of 20 patients
suffered from events: five patients did not respond to
chemotherapy, seven had a partial response, and eight
relapsed.
Clinical/CT scan results 
Sixty-five patients (47%) were assigned to the bulky
group, having superficial (n=33) and/or mediastinal (n=44)
lymph node masses. Twelve simultaneously had superfi-
cial and mediastinal masses. The median of long axis
measurements of the masses was 7 cm (range, 5-12). No
patient had abdominal bulky lymph nodes. The remain-
ing 72 patients had lymph nodes with a diameter < 5 cm.
Power Doppler US results 
The average time required for the power Doppler US
examination was 30 minutes (range, 20-50).
Intraobserver and interobserver measurement repro-
ducibility was excellent, with a Pearson’s value of 0.9
and 0.88, respectively. Twenty-six patients (20%) were
assigned to the power Doppler US-defined bulky group.
The median of the selected lymph node volume meas-
urements was 37.5 mL (range, 30-180); depth was
between 1 and 4 cm, and the site was cervical in four,
supraclavicular in five, axillary in 13, pectoral in two,
and inguinal in two. Lymph nodes were round in 18
cases and oval in eight; the hilus was absent in 16 cases
and truncate in ten. Intranodal vascular mapping was
mixed in 13 cases, chaotic in ten, peripheral in two, and
central/hilar in one (Figure 1). At Doppler spectral analy-
sis, the median RI value was 0.74 (range 0.65-0.95).
There was complete agreement on bulky disease identi-
fication between power Doppler-US and PET/CT scans
in 13 patients studied by both methods; the volume of
the PET/CT-selected bulky lymph nodes ranged from
30 to 60 mL and the SUV from 7 to 13. The remaining
111 patients had superficial lymph nodes with a volume
< 30 mL or ≥30 mL without hypervascularization. 
Overall, the designation of superficial sites containing
bulky disease was concordant between clinical/CT
scans and power Doppler US in 18 patients and discor-
dant in 23 patients.
Table 1. Characteristics of the entire study population.
Characteristics No. (%)
Total patients 137 
Sex
Male 79 (57)
Female 58 (43)
Age, years
Median 30
Range 15-74 
Histology
Nodular sclerosis 96 (70)
Mixed cellularity 34 (25)
Lymphocyte Predominance 7 (5)
No. of nodal sites involved
2 47 (34)
3 50 (36)
> 3 40 (30)
Contiguous extranodal involvement* 22 (16)
Ann Arbor Stage
I 14 (10)
II 90 (66)
III 28 (20)
IV 5 (4)
Splenic involvement° 20 (14)
B symptoms 75 (55)
Erythrocyte sedimentation rate ≥ 50 mm 80 58)
Mediastinal bulky 44 (32)
Clinical/CT-selected superficial bulky disease 33 (24)
Power Doppler US-selected bulky disease 26 (20)
*an extranodal extension of the disease confined to a single lung lobe, or to sites
such as pericardium/pleura/chest wall/pharynx, contiguous to the lymph nodes
involved; °focal lesion(s) visible on CT, FDG-PET and/or US scanning. 
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Risk factors for FFTF
In a univariate analysis for prognostic factors, power
Doppler US-selected bulky disease surpassed the medi-
astinal and superficial bulky disease selected by clini-
cal/CT scan evaluation and any other analyzed factor as
a significant predictor of FFTF. When a multivariate
analysis was performed, only power Doppler US-select-
ed bulky disease and advanced stage retained statistical-
ly significant prognostic value, and again power
Doppler US was the best indicator of prognosis.
Mediastinal bulky disease retained borderline statistical
significance (Table 2).
Discussion
Stringent criteria for defining bulky disease are still
controversial. According to various authors, bulky dis-
ease is considered any node mass whose largest diame-
ter is at least 5 cm, 7 cm, or 10 cm.1,11-13 However, one-
dimensional measurement is often inaccurate in reliably
determining lymph node size. On the other hand, not
all enlarged lymph nodes are involved by the main dis-
ease entity; there is a risk of considering as malignant
satellite lymph nodes that are reactive, necrotic or
steato-fibrotic. We designed the present prospective
study to test the hypothesis that a combined study of
lymph node volume and angioarchitecture by power
Doppler US may provide a more accurate estimation of
bulky disease in patients with Hodgkin’s lymphoma.
The low intraobserver and interobserver variability of
US assessment of volume, and the strong correlation
between bulky lymph node selected by power Doppler
US and PET/CT scanning (that measure both mass vol-
ume and activity) confirmed the high reliability of the
method. The results of this study show that power
Figure 1. Power
Doppler ultrasound
(US) features.
Peripheral type (A),
mixed type (B),
chaotic type (C), and
central type (D) vas-
cularization in bulky
lymph nodes (volume
≥30 mL) as revealed
by power Doppler US
scanning in patients
with Hodgkin’s lym-
phoma.
Table 2. Search for factors predicting freedom from treatment failure: univariate and multivariate analyses.
Factor FFTF (%) p univariate HR 95% CI p multivariate HR 95% CI
Female/Male 82 (78) 0.73 1.1 0.46-3.01 0.2 0.51 0.18-1.44
Age, years: <45/≥45 78 (69) 0.097 0.48 0.2-1.14 0.92 0.94 0.27-3.27
Stage: I/II vs III/IV 86 (68) 0.002 3.88 1.63-9.26 0.02 3.61 1.25-10.41
B symptoms: No/Yes 95 (67) 0.003 6.02 1.78-20.3 0.26 2.2 0.56-8.6       
Nodal sites involved: <3/≥3 87 (70) 0.25 1.56 0.735-3.29 0.41 0.58 0.16-2.11
Contiguous extranodal involvement*: No/Yes 82 (67) 0.02 2.79 1.17-6.64 0.61 1.31 0.46-3.77
Erythrocyte sedimentation rate: <50/≥50 86 (70) 0.17 1.8 0.771-4.22 0.95 1.04 0.35-3.07
Mediastinal bulky: No/Yes 88 (62) 0.03 2.56 1.11-5.93 0.06 3.07 0.93-10.16
Clinical/CT-selected superficial bulky: No/Yes 82 (78) 0.64 1.25 0.49-3.2 0.11 0.34 0.09-1.3
Power Doppler US-selected bulky: No/Yes 88 (47) <0.001 7.9 3.37-18.5 <0.001 9.86 3.1-31.39
*an extranodal extension of the disease confined to sites contiguous to the lymph nodes involved. 
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Doppler US leads to a better prognostic classification
than does clinical/CT scan evaluation and surpasses sev-
eral other commonly evaluated risk factors, predicting
FFTF more properly.
The reason why lymph nodes estimated by different
methods may have variable prognostic significance has
anatomical bases. Clinical/CT scan evaluation using
one-dimensional measurement, without informations
on the vascular characteristics of the lymph node, is
generally unable to differentiate between viable tumor
and necrosis, inflammation or fibrosis in the mass. In
power Doppler US-selected lymph nodes, the magni-
tude of neoangiogenesis is probably the most relevant
finding. The various steps of neoplastic angiogenesis
lead to the development of abnormal vascularization,
with defective wall structure, stenoses, occlusion, vessel
dilation or arterovenous shunts.14 The neoangiogenesis
network is recognized as being critical for tumor
growth, invasion and metastasis. In situ data in lym-
phoma tissue showed that angiogenesis increases with
tumor progression (in terms of increasing grade of
malignancy).15,16
In conclusion, power Doppler US may provide more
standardized and uniform criteria for detecting true
bulky disease. These results need to be confirmed in
large prospective studies, which may include the use of
contrast agent enhanced US.17 Our data support the con-
cept of clinical heterogeneity in patients with Hodgkin’s
lymphoma. Neoangiogenesis-induced hypervascular-
ization of bulky lymph nodes may be implicated in
more aggressive behavior of the disease; thus, patients
with true bulky disease may benefit from more inten-
sive treatment.11-13
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